IP Waiver Proposal Won’t Hold Back Moderna’s Rise

Bancel: 'IP Is Not The Issue'

 
• By Andrew McConaghie

While White House support for an intellectual property waiver has been cheered by access campaigners, Moderna said it won’t help solve the pandemic’s big vaccine production challenges any time soon.

The Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on on December 2, 2020, where the biotechnology company is mass producing its Covid-19 vaccine.
Moderna has already booked advance sales of $19.2bn for its COVID-19 vaccine this year, with more to come. (JOSEPH PREZIOSO/AFP via Getty Images)

More from Business

More from Scrip